30.07.2014 22:13:05

Novavax to Host Conference Call to Discuss Second Quarter 2014 Financial Results on August 6, 2014

ROCKVILLE, Md., July 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that it will report its financial results for the second quarter of 2014 on Wednesday, August 6, 2014, after market close.

In addition, management will host a conference call, to discuss the quarterly financial results and provide an update on corporate activities. Conference call details are as follows:

Date:August 6, 2014Time:4:30 PM US eastern timeDial-in number:1 (877) 212-6076 (domestic) or 1 (707) 287-9331 (international)Via Web:www.novavax.com

Conference call Replay:

Dates:Starting at 6:31pm on August 6, 2014 until midnight October 6, 2014Dial-in number:1 (855) 859-2056 (domestic) or 1 (404) 537-3406 (international) Passcode:82216889Via-Web:www.novavax.com, "Investor Info"/"Events"

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com.

CONTACT: Barclay Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000

This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#1844196

Nachrichten zu Novavax Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Novavax Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!